Bank Of America Corp X4 Pharmaceuticals, Inc Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Bank Of America Corp holds 111,017 shares of XFOR stock, worth $37,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares

111,017

Previous 90,957 22.05%

Holding current value

$37,745

Previous $52,000 42.31%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.86 $10,832 - $17,251	20,060 Added 22.05%	111,017 $74,000
Q2 2024 Aug 14, 2024	SELL	$0.58 - $1.47 $6,817 - $17,279	-11,755 Reduced 11.44%	90,957 $52,000
Q1 2024 May 15, 2024	SELL	$0.72 - $1.46 $79,326 - $160,856	-110,176 Reduced 51.75%	102,712 $142,000
Q4 2023 Feb 14, 2024	BUY	$0.61 - $0.99 $102,510 - $166,369	168,050 Added 374.79%	212,888 $178,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $36,767 - $111,646	44,838 New	44,838 $86,000
Q4 2022 Feb 10, 2023	BUY	$0.69 - $2.21 $186 - $598	271 Added 27100.0%	272 $0
Q2 2022 Aug 12, 2022	SELL	$0.88 - $1.91 $5,494 - $11,926	-6,244 Reduced 99.98%	1 $0
Q1 2022 May 16, 2022	SELL	$1.48 - $2.58 $4,678 - $8,155	-3,161 Reduced 33.61%	6,245 $11,000
Q4 2021 Feb 08, 2022	SELL	$1.9 - $5.6 $14,774 - $43,545	-7,776 Reduced 45.26%	9,406 $22,000
Q3 2021 Nov 15, 2021	SELL	$4.53 - $6.45 $24,172 - $34,417	-5,336 Reduced 23.7%	17,182 $91,000
Q2 2021 Sep 13, 2021	BUY	$6.49 - $9.56 $146,141 - $215,272	22,518 New	22,518 $147,000

Others Institutions Holding XFOR

# of Institutions

105

Shares Held

100M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp X4 Pharmaceuticals, Inc Transaction History